

phenotype prediction from genotype (version 3.4)

I. General information

Patient:	Study Id:
Birth date:	Viral load:
Sample received:	Sample collected:
Sample ID: 32	Predicted subtype: B (100%)
Sample type:	Report date: October 6, 2018
Physician:	Reported by:

II. Substitutions (relative to the reference strain HXB2)

Protease:	V3I, L10I, V11I, T12K, I13V, K20V, V32I, L33F/L, E35G, M36I, S37D/N, M46I, I47V, I54M, R57K, Q58E, L63P, I64V, A71I/V, G73S, I84I/V, L89V, L90M
Reverse transcriptase:	

III. Phenotype prediction

Drug	Resistance Factor RF (*)	z-score	Scored Positions (**)
ZDV	0	0	
ddI	0	0	
d4T	0	0	
3TC	0	0	
ABC	0	0	
TDF	0	0	
NVP	0	0	
EFV	0	0	
ETR (***)	Susceptible		
RPV (***)	Susceptible		
SQV	141.209	14.249	48G <u>84V</u> <u>74T</u> 88N <u>90M</u> <u>47V</u> <u>53F</u> 95C <u>26T</u> <u>11I</u> <u>1P</u> 80T <u>35G</u> <u>34E</u> <u>97L</u>
IDV	315.352	15.029	82V 88N <u>90M</u> <u>29D</u> <u>1P</u> <u>84V</u> <u>21E</u> <u>65E</u> <u>20V</u> <u>32I</u> <u>46I</u> <u>10I</u> <u>85I</u> <u>30D</u> <u>73S</u>
NFV	665.846	14.744	88N 30D <u>90M</u> <u>84V</u> <u>82V</u> 97L 68G <u>46I</u> <u>31T</u> 75V 74T 5L 2Q 1P 29D
APV	1801.621	23.369	<u>33F</u> <u>76L</u> 50I <u>84V</u> <u>54M</u> <u>32I</u> <u>89V</u> <u>46I</u> <u>85I</u> <u>47V</u> <u>37D</u> <u>22A</u> <u>63P</u> <u>1P</u> <u>82V</u>
LPV	221.878	15.764	82V 50I <u>46I</u> <u>84V</u> <u>33F</u> <u>76L</u> <u>89V</u> <u>22A</u> <u>7Q</u> <u>63P</u> <u>24L</u> <u>47V</u> <u>25D</u> <u>54M</u> <u>37D</u>
TPV	27.664	7.174	<u>69H</u> <u>46I</u> <u>48G</u> <u>84V</u> <u>90M</u> <u>47V</u> <u>72I</u> <u>15I</u> <u>91T</u> <u>71V</u> <u>73S</u> 82V 74T 88N 19L
DRV	149.725	13.281	<u>47V</u> <u>33F</u> <u>84V</u> <u>76L</u> <u>74T</u> <u>43K</u> <u>54M</u> <u>37D</u> <u>65E</u> <u>48G</u> <u>32I</u> <u>93I</u> <u>15I</u> <u>7Q</u> <u>8R</u>
ATV	468.782	18.389	48G <u>84V</u> <u>82V</u> <u>90M</u> <u>4T</u> <u>33F</u> <u>88N</u> <u>35G</u> <u>7Q</u> <u>73S</u> <u>24L</u> <u>76L</u> <u>54M</u> <u>45K</u> <u>32I</u>


(*) based on LIBSVM, Copyright (c) 2000, Chih-Chung Chang and Chih-Jen Lin

(**) Positions are ordered according to their impact on the phenotype prediction. Differences with respect to HXB2 are underlined. Positions shown in red and in green contribute to an increase or decrease in resistance, respectively. At most 15 positions are shown for each drug.

(***) Resistance predictions and scored mutations for ETR and RPV were performed with rules-based drug-resistance interpretation models by HIV-GRADE (<http://www.hiv-grade.de>)

IV. Interpretation

Patient:	Birth date:	Sampling date:
Current therapy:		Viral load:



■ susceptible ■ intermediate ■ resistant

(*)number of standard deviations above mean of drug naive patients. Negative z-scores may indicate hypersusceptibility.

NRTIs/NtRTI:

NNRTIs:

PIs:

Previous genotypes:

date

signature